Mono Pharmacare Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2023 . The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2023 . The Revenue of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Mono Pharmacare Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Vaishali Pharma Ltd?

Market cap of Mono Pharmacare Ltd is 23 Cr while Market cap of Vaishali Pharma Ltd is 99 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Vaishali Pharma Ltd?

The stock performance of Mono Pharmacare Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Vaishali Pharma Ltd?

As of May 3, 2026, the Mono Pharmacare Ltd stock price is INR ₹13.25. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.61.

How do dividend payouts of Mono Pharmacare Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.